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Background: A long non-coding RNA hox transcript antisense intergenic RNA (HOTAIR) is in-
volved in epigenetic regulation through chromatin remodeling by recruiting polycomb repressive 
complex 2 (PRC2) proteins (EZH2, SUZ12, and EED) that induce histone H3 trimethylation at ly-
sine 27 (H3K27me3). Deregulation of c-MYC and interaction between c-MYC and EZH2 are well 
known in lymphomagenesis; however, little is known about the expression status of HOTAIR in 
diffuse large B-cell lymphomas (DLBCLs). Methods: The expression status of PRC2 (EZH2, 
SUZ12, and EED), H3K27me3, c-MYC, and BCL2 was analyzed using immunohistochemistry (n 
= 231), and HOTAIR was investigated by a quantification real-time polymerase chain reaction 
method (n = 164) in DLBCLs. Results: The present study confirmed the positive correlation among 
PRC2 proteins, H3K27me3, and c-MYC in DLBCLs. Expression level of HOTAIR was also posi-
tively correlated to EZH2 (p < .05, respectively). Between c-MYC and HOTAIR, and between c-
MYC/BCL2 co-expression and HOTAIR, however, negative correlation was observed in DLBCLs 
(p < .05, respectively). High level of H3K27me3 was determined as an independent prognostic 
marker in poor overall survival (hazard ratio, 2.0; p = .023) of DLBCL patients. High expression of 
HOTAIR, however, was associated with favorable overall survival (p = .004) in the univariate analy-
sis, but the impact was not significant in the multivariate analysis. The favorable outcome of 
DLBCL with HOTAIR high expression levels may be related to the negative correlation with c-
MYC expression or c-MYC/BCL2 co-expression. Conclusions: HOTAIR expression could be one 
of possible mechanisms for inducing H3K27me3 via EZH2-related PRC2 activation, and induced 
H3K27me3 may be strongly related to aggressive DLBCLs which show poor patient outcome.
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▒ ORIGINAL ARTICLE ▒
Long non-coding RNAs (lncRNAs) are molecules longer than 
200 nucleotides that are not translated into proteins. The role 
of lncRNAs is mostly unknown. Recently, several types of can-
cer-related lncRNAs have been identified and studied in the 
field of translational research.1-4 According to recent studies, 
some lncRNAs are involved in the epigenetic regulation of pro-
tein coding genes. Hox transcript antisense intergenic RNA (HO-
TAIR) is one of most actively studied lncRNAs. Overexpression 
of HOTAIR is known to occur in various solid tumors of esopha-
gus, stomach, colon, liver, pancreas, lung, and breast and is relat-
ed to poor prognosis in those tumors.3,5 HOTAIR is located with-
in the homeobox C (HOXC) gene cluster on chromosome12 and 
is co-expressed with the HOXC genes. HOTAIR is involved in 
chromatin remodeling through recruiting polycomb repressive 
complex 2 (PRC2; enhancer of zeste homolog 2 [EZH2], sup-
pressor of zeste 12 homolog [SUZ12], and embryonic ectoderm 
development [EED]) and then inducing histone modification 
such as histone H3 trimethylation at lysine 27 (H3K27me3) at the 
promoter site of protein-coding genes.1-4 Chromatin remodel-
ing and gene regulation via histone modification of the polycomb 
repressive complex is known to function in the development of 
embryonic stem cells as well as the development of many types 
of cancers including hematologic malignancies.6,7 
In hematologic malignancies, especially in diffuse large B cell 
lymphomas (DLBCLs) and follicular lymphomas that are the 
most predominant lymphoma subtype, the deregulation of 
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EZH2 methyltransferase is well known. In our previous study, 
the high level of global H3K27me3 in DLBCL was associated 
with poor patient prognosis.8 From these findings, it was sug-
gested that HOTAIR might be involved in the PRC2-associated 
induction of H3K27me3 in DLBCLs; however, an association 
with HOTAIR and DLBCL has not yet been described. In the 
present study, the expression status of HOTAIR was investigat-
ed in DLBCL, and the association with PRC2 and H3K27me3 
was analyzed. 
MATERIALS AND METHODS
Patients and clinical data
A total of 231 cases of DLBCL treated with R-CHOP (ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and predni-
sone) or R-CHOP–like (with or without radiotherapy or sur-
gery) chemotherapy were selected for the study. Cases were 
retrieved from the archival files from the Department of Pathol-
ogy, Severance Hospital, from 2005 to 2011. All cases were in-
dependently reviewed by two pathologists (S.O.Y. and S.H.K.) 
based on current World Health Organization criteria,9 and dis-
cordant cases were consulted to other expert hematopatholo-
gists. In HOTAIR expression analysis, 164 cases were selected 
from the above 231 cases and investigated after quality assess-
ment of extracted RNA. Clinical data were obtained from medi-
cal records. All study protocols were performed according to 
the ethical guidelines of the ‘‘World Medical Association Decla-
ration of Helsinki–Ethical Principles for Medical Research In-
volving Human Subjects.’’ This study was approved by the In-
stitutional Review Board of Severance Hospital. 
Analysis for HOTAIR expression
Formalin fixed paraffin embedded (FFPE) tissue sections were 
prepared and stained with hematoxylin and eosin, and then the 
tumor areas were confirmed and marked under the microscope. 
The marked areas mainly contained packed tumor cells, and the 
stromal component was less than 10% of the marked area. The 
unstained slides of FFPE tissues were prepared after dissecting 
FFPE tissue blocks at 10-mm thickness using a microtome, and 
the marked area was scraped using a scalpel blade. Generally, 
three slices of tissue section per case were used for RNA extrac-
tion. Total RNA was isolated using an RNeasy FFPE Kit (Qia-
gen, Hilden, Germany) according to the supplier’s instructions. 
Extracts of RNA were verified by measuring the ratios ofA260/
A280 and A260/A230 with a ND-1000 NanoDrop spectropho-
tometer (NanoDrop, Wilmington, DE, USA). Reverse tran-
scription was performed using a QuantiTect Reverse Transcrip-
tion kit (Qiagen). The expression patterns of HOTAIR were 
assayed by relative quantification using expression of the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Primers for HOTAIR and GAPDH were as follows: 
HOTAIR (forward, 5'-AGCCAGAGGAGGGAAGAGAG-3'; 
reverse, 5'-TCCCGTTCCCTAGATTTTCC-3') and GAPDH 
(forward, 5'-CAAATTCCATGGCACCGTCA-3'; reverse, 
5'-ATCGCCCCACTTGATTTTGG-3'). Primers of HOTAIR 
were designed to detect all three transcript variants (transcript 
variant 1, 3, and 2). In brief, a 20 μL mixture containing 1.0 μL 
of cDNA, power SYBR Green PCR Master Mix (Applied Bio-
systems, Carlsbad, CA, USA), 1.0 μL of 10 pmol/μL forward 
primer, 1.0 μL of 10 pmol/μL reverse primer, and 7.0 μL of ter-
tiary distilled water was prepared. Amplification was performed 
using a Step One Plus Real-Time PCR instrument (Applied 
Biosystems) under the following conditions: denaturation at 
94°C for 10 minutes, followed by 35 cycles of 94°C for 15 sec-
onds, 55°C for 30 seconds, and 72°C for 30 seconds (fluorescence 
signal acquisition was performed at this phase). Immediately 
after amplification, melting curve analysis was performed for 
amplicon verification. All samples were analyzed in triplicate to 
confirm reproducibility. Using the Step One Plus Real-Time 
PCR System software ver. 2.1 (Applied Biosystems), the thresh-
old cycle (Ct, beginning of the polymerase chain reaction expo-
nential phase) value of amplified HOTAIR was normalized ver-
sus that of amplified GAPDH (2-dCt). After quality assessment 
of extracted RNA and expression analysis of the housekeeping 
gene GAPDH, 164 cases were finally selected for the analysis of 
HOTAIR expression. Normal palatine tonsil tissue was obtained 
from 10 cancer-free individuals and used as age-matched cancer-
free controls. The cutoff value for high expression of HOTAIR 
(HOTAIRhigh) was determined at the uppermost value among 
those of normal control tonsil tissues.
Tissue microarray preparation, immunohistochemistry, and 
analysis
The hematoxylin and eosin slides were reviewed and two rep-
resentative core tissues of the tumor area were selected in each 
case. Core tissues (3 mm in diameter) were taken from the indi-
vidual donor blocks and arranged in new recipient tissue micro-
array paraffin blocks using a trephine apparatus. Immunohisto-
chemical staining and in situ hybridization were performed on 
4-μm tissue microarray tissue sections. Immunohistochemistry 
of EZH2 (1:100, Invitrogen, Carlsbad, CA, USA), SUZ12 (1:50, 
Abcam, Cambridge, UK), EED (1:1,000, Abcam), H3K27me3 
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(1:100, clone C36B11, Cell Signaling Technology, Beverly, MA, 
USA) was performed using the Ventana BenchMark XT Auto-
stainer (Ventana Medical Systems, Tucson, AZ, USA). Immuno-
histochemistry for c-MYC (1:50, clone Y69, Abcam), BCL2 
(1:50, Novocastra, Newcastle, UK), CD10 (1:100, Novocastra), 
BCL6 (RTU, Novocastra), and MUM1 (1:200, Cell Marque, 
Rocklin, CA, USA) was performed using the LEICA BOND-
III Autostainer (Leica Biosystems, Newcastle Upon Tyne, UK). 
For in situ hybridization for Epstein-Barr virus (EBV), the IN-
FORM EBER probe (Ventana Medical Systems) was used with 
the Ventana BenchMark XT Autostainer (Ventana Medical Sys-
tems) and ISH iVIEW Blue Detection kit (Ventana Medical Sys-
tems).
For EZH2, SUZ12, EED, and H3K27me3, staining intensity 
(0, no staining to weak; 1, moderate to strong) and proportion 
of positive tumor cell nuclei (0, < 10%; 1, ≥ 10% and < 75%; 2, 
≥ 75%) were semiquantitatively graded as in the previous study.8 
Based on the intensity multiplied by proportion, the protein ex-
pression was scored as low (0), intermediate (1), or high level (2). 
For CD10, BCL6, and MUM1, the positive cutoff value was de-
termined according to the Hans classification criteria10 and was 
considered positive if ≥ 30% of the tumor cells showed nuclear 
immunoreactivity for BCL6 and MUM1, and if ≥ 30% of cells 
showed membranous reactivity for CD10. Determination of the 
germinal center B-like (GCB) or non-GCB phenotype was based 
on the Hans algorithm 10.
For c-MYC and BCL2, staining intensity (0, no staining to 
weak; 1, moderate to strong) and areas of positive tumor cell nu-
clei by 10% increments (1 of < 10% to 10 of 90%–100%) were 
semiquantitatively graded. The cutoff value for high expression 
was determined by log-rank tests (Mantel-Cox) for overall sur-
vival as in the previous report, and the threshold value was de-
termined for c-MYC at a score ≥ 4 (≥ 40% of tumor cells with 
moderate to strong expression), and BCL2 at a score ≥ 7 (≥ 70% 
of tumor cells with moderate to strong expression).11,12 For EBV 
in situ hybridization, the threshold value was determined when 
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Fig. 1. A case of DLBCL with HOTAIRhigh (A–F) shows the various expression pattern of c-MYC (A), EZH2 (B), SUZ12 (C), EED (D), global 
H3K27me3 (E), and BCL2 (F). In a DLBCL case of HOTAIRhigh (A–F), many PRC2 protein (EZH2, SUZ12, and EED)–positive tumor cells show 
no expression of c-MYC and no mark of H3K27me3. BCL2 was negative in this case. DLBCL, diffuse large B-cell lymphoma; HOTAIR, hox 
transcript antisense intergenic RNA; EZH2, enhancer of zeste homolog 2; SUZ12, suppressor of zeste 12 homolog; EED, embryonic ecto-
derm development; PRC2, polycomb repressive complex 2.
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≥ 10% of the tumor cells showed moderate to strong nuclear 
expression. 
The features of expression of polycomb repressive complex 
proteins (EZH2, SUZ12, and EED), H3K27me3, c-MYC, and 
BLC2 in HOTAIRhigh or HOTAIRlow cases are presented in Fig. 1.
Statistical analysis
The t test and chi-square test were used to analyze the differ-
ences between the variables examined. Overall survival times 
were measured from the date of lymphoma diagnosis to the date 
of death or last follow-up visit. Patient survival rates were deter-
mined using the Kaplan-Meier method, and the differences in 
survival rates were compared using the log-rank test. Multivari-
ate analysis was performed using the Cox proportional hazards 
model. A two-sided p-value < .05 was considered to be statistical-
ly significant. When a two-sided p-value was ≤ .05 and < .10, a 
trend toward statistical significance was considered. All statisti-
cal analyses were carried out using SPSS software ver. 20.0 for 
Windows (IBM Corp., Armonk, NY, USA).
RESULTS
The relations among PRC2 proteins, H3K27me3, c-MYC, 
BCL2, and HOTAIR
The DLBCL cases frequently showed high expression of 
PRC2 proteins and H3K27me3 (28.9%, 47.1%, 74.3%, and 
35.7% for EZH2high, SUZ12high, EEDhigh, and H3K27me3high, 
respectively). High expression of all PRC2 proteins (EZH2high/
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Fig. 2. (A) The DLBCL cases frequently show high expression of PRC2 proteins (EZH2, SUZ12, and EED), high expression of all PRC2 pro-
teins (EZH2high/SUZ12high/EEDhigh), and high H3K27me3 level. (B) When compared to cases without high H3K27me3 expression (low H3K-
27me3), those with high H3K27me3 expression more frequently show high expression of EZH2, SUZ12, EED, and all PRC2 (EZH2high/SU-
Z12high/EEDhigh). (C) When compared to cases without high c-MYC expression (low c-MYC), those with high c-MYC expression more 
frequently show high expression of EZH2, SUZ12, EED, all PRC2 (EZH2high/SUZ12high/EEDhigh), H3K27me3, and BCL2. (D) The expression 
level of HOTAIR is significantly higher in cases with high EZH2 expression than those without high EZH2 expression (low EZH2). DLBCL, dif-
fuse large B-cell lymphoma; HOTAIR, hox transcript antisense intergenic RNA; EZH2, enhancer of zeste homolog 2; SUZ12, suppressor of 
zeste 12 homolog; EED, embryonic ectoderm development; PRC2, polycomb repressive complex 2. *p < .05, **p < .001.
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SUZ12high/EEDhigh) was noted in 16.1% of cases (Fig. 2A). The 
expression of H3K27me3 was positively correlated to PRC2 
markers. When compared to cases of H3K27me3low, those of 
high H3K27me3 expression more frequently showed high ex-
pression of EZH2 (41.2% vs 22.2%, p = .003), SUZ12 (62.5% 
vs 43.0%, p = .053), EED (88.6% vs 69.7%, p = .026), and all 
PRC2 (EZH2high/SUZ12high/EEDhigh) (32.3% vs 11.3%, p = .005). 
These results are summarized in Fig. 2B.
The expression of c-MYC was positively correlated to PRC2 
markers and H3K27me3. When compared to cases of c-MY-
Clow, those of high c-MYC expression more frequently showed 
high expression of EZH2 (39.1% vs 24.6%, p = .036), SUZ12 
(72.2% vs 32.1%, p < .001), EED (85.7% vs 66.7%, p = .011), 
all PRC2 (EZH2high/SUZ12high/EEDhigh) (26.4% vs 9.5%, p = 
.009), and H3K27me3 (40.6% vs 21.2%; p = .004). BCL2 was 
positively correlated with c-MYC (49.3% vs 26.8%; p = .002). 
These results are summarized in Fig. 2C. BCL2 expression 
showed no significant correlation with the tested PRC2-related 
markers.
The expression level of HOTAIR was significantly higher in 
cases of EZH2high than those of EZH2low (mean ratio value, 207 
vs 66; p = .027) (Fig. 2D). For other markers, no statistical signif-
icance was observed according to HOTAIR expression level. 
HOTAIR expression in in relation to clinicopathological 
variables of DLBCL
In the present study, 23.8% of cases (39/164) showed high 
HOTAIR expression levels (HOTAIRhigh). In the correlation 
analysis between HOTAIRhigh and clinicopathological character-
istics of DLBCL (Table 1), high expression of c-MYC protein 
was less frequent in HOTAIRhigh than in HOTAIRlow (p = .037). 
The rate of co-expression of c-MYC and BCL2 was significantly 
lower in HOTAIRhigh than in HOTAIRlow (p = .015). Other clini-
copathological factors including EBV (p = .660) and Hans clas-
sification (p = .746) showed no significant correlation with HO-
TAIR expression (Table 1).
Clinical significance of RNA and protein expression 
In univariate analysis for overall survival of DLBCL patients 
(Table 2), the known prognostic factors including age > 60 (p < 
.001), Eastern Cooperative Oncology Group performance status 
≥ 2 (p < .001), elevated lactate dehydrogenase (p < .001), extra-
nodal sites ≥ 2 (p = .001), Ann-Arbor stage III–IV (p = .003), and 
International Prognostic Index (IPI) risk ≥ 3 (p < .001) showed 
significant association with reduced overall survival rate. Expres-
sion of c-MYC and co-expression of c-MYC/BCL2 were also re-
lated to inferior overall survival rate (p = .032 and p = .006, re-
spectively). Among the PRC pathway markers (EZH2, SUZ12, 
EED, and H3K27me3), SUZ12high and H3K27me3high were re-
lated to inferior overall survival rate (p = .028 and p = .010, re-
spectively) (Fig. 3A, B). HOTAIRhigh, however, was significantly 
related to superior overall survival rate than HOTAIRlow (p = 
.004) (Fig. 3C).
In multivariate analysis (Table 2), H3K27me3high revealed an 
independent effect on poor overall survival (hazard ratio, 2.0; p = 
.023). IPI risk ≥ 3 was still determined as an independent prog-
nostic factor (hazard ratio, 3.5; p < .001), while HOTAIRhigh 
showed a tendency to be related to improved survival with 
marginal significance (hazard ratio, 0.5; p = .086). 
 
DISCUSSION
In our previous study, high level of global H3K27me3 was 
found to be a negative prognostic indicator in patients with 
DLBCL.8 This subsequent study aimed to explore the role of 
HOTAIR, possibly functioning via induction of H3K27me3. We 
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Fig. 3. Overall survival based on SUZ12 (A), H3K27me3 (B), and HOTAIR expression (C). High expression of SUZ12 (SUZ12high) and H3K-
27me3 (H3K27me3high) is related to inferior overall survival, while high expression of HOTAIR (HOTAIRhigh) is correlated with longer overall sur-
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ic RNA.
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found the positive correlation between PRC2 proteins, global 
H3K27me3 levels, and c-MYC in DLBCL as expected. 
In the present study, the positive correlation among PRC2 
proteins (EZH2, SUZ12, and EED), global H3K27me3 levels, 
and c-MYC was also confirmed in DLBCL as expected. In addi-
tion, HOTAIR expression was related to EZH2 expression. These 
findings could support that the lncRNA HOTAIR may be in-
volved in inducing H3K27me3 through recruiting polycomb 
repressive complex, the methyltransferase EZH2 and core ac-
cessory proteins, SUZ12 and EED. 
Based on many other studies, interaction between c-MYC 
and PRC2 (EZH2, SUZ12, and EED) is well known in the tu-
morigenesis of various cancer types including lymphomas. Pro-
tein c-MYC interacts with EZH2 as well as SUZ12/EED, and 
they induce the histone modification of H3K27me3 on the pro-
moter of target genes, which then represses gene expression. 
Many other studies have shown that EZH2 and c-MYC activate 
each other.13-15 From the present findings, it could be also sug-
gested that c-MYC may be the possible mechanism for induc-
ing H3K27me3 via PRC2-related pathways in DLBCLs.
Table 1. Clinicopathological characteristics, relation to outcome, and association with HOTAIR level in DLBCL patients
Variable No. (%) (n = 164)
HOTAIR
p-value
HOTAIRlow HOTAIRhigh
Sex
Male 98 (59.8) 73 (58.4) 25 (64.1) .526
Female 66 (40.2) 52 (41.6) 14 (35.9)
Age (yr)
≤ 60 94 (57.3) 69 (55.2) 25 (64.1) .326
> 60 70 (42.7) 56 (44.8) 14 (35.9)
ECOG performance statusa
< 2 132 (80.5) 96 (76.8) 36 (92.3) .033
≥ 2 32 (19.5) 29 (23.2) 3 (7.7)
Ann-Arbor stagea
I–II 89 (54.6) 63 (50.8) 26 (66.7) .083
III–IV 74 (45.4) 61 (49.2) 13 (33.3)
Extranodal sitesa
< 2 108 (66.3) 81 (65.3) 27 (69.2) .653
≥ 2 55 (33.7) 43 (34.7) 12 (30.8)
Lactate dehydrogenasea
Normal 90 (55.2) 65 (52.4) 25 (64.1) .201
Elevated 73 (44.8) 59 (47.6) 14 (35.9)
IPI risk groupa 79 (63.7) 28 (71.8) .354
0–2 107 (65.6) 45 (36.3) 11 (28.2)
3–5 56 (34.4)
Hans classificationa
GCB 44 (28.0) 32 (27.1) 12 (30.8) .660
Non-GCB 113 (72.0) 86 (72.9) 27 (69.2)
EBV
Negative 132 (88.0) 98 (87.5) 34 (89.5) .746
Positive 18 (12.0) 14 (12.5) 4 (10.5)
BCL2a
Negative expression 84 (58.7) 58 (54.7) 26 (70.3) .098
Positive expression 59 (41.3) 48 (45.3) 11 (29.7)
c-MYCa
Negative expression 92 (62.2) 63 (57.3) 29 (76.3) .037
Positive expression 56 (32.8) 47 (42.7) 9 (23.7)
c-MYC/BCL2a
No co-expression 110 (77.5) 76 (72.4) 34 (91.9) .015
Co-expression 32 (22.5) 29 (27.6) 3 (8.1)
Values are presented as number (%). 
HOTAIR, hox transcript antisense intergenic RNA; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, International 
Prognostic Index; GCB, germinal center B-like; EBV, Epstein-Barr virus. 
aInformation not available in some cases.
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In other studies of solid tumors originating from various or-
gans, high expression of HOTAIR showed a close association with 
poor prognosis.5 In the present study, however, high levels of 
HOTAIR expression showed an association with good prognosis 
in DLBCL, although the impact was not significant in the mul-
tivariate analysis. There are no comparable reports to support the 
present findings because this is the first study for the expression 
status of HOTAIR in hematologic malignancies.
Although interaction between c-MYC and HOTAIR has not 
been established in hematologic malignancies, a close relation-
ship between them may be plausible when considering the close 
association of PRC2 and HOTAIR, and PRC2 and c-MYC. 
However, expression of c-MYC showed a negative correlation 
with HOTAIR in the present study. One of the possible reason 
is autoregulation of c-MYC reported in one study; c-MYC re-
presses itself via forming autoregulatory loops with EZH2,13 
therefore, HOTAIR might be involved in that process via EZH2.
Whether HOTAIR expression is directly linked to the suppres-
sion of c-MYC or H3K27me3 should be investigated in further 
functional studies. In the HOTAIR-related suppression of c-
MYC, PRC2-associated histone modification (H3K27me3) 
might be induced in the promoter region of c-MYC gene. For 
confirmation of this possible modulation, further study should 
be followed.
The favorable outcome of DLBCLs with high HOTAIR expres-
sion might be associated with the negative correlation with c-
MYC and/or BCL2. Recent evidence has shown that co-expres-
sion of c-MYC and BCL2 proteins is associated with poor prog-
nosis in DLBCL patients regardless of gene signature.11,12 This 
was also observed in the present study in the univariate survival 
analysis. When the factor of HOTAIR expression was added in 
the multivariate analysis; however, the prognostic effect of co-
expression of c-MYC and BCL2 became weak, and only the fac-
tor of high H3K27me3 level was important as well as the IPI 
risk score. H3K27me3, the chromatin modification status in-
duced via changes of HOTAIR, c-MYC, or other various known 
and unknown mechanisms, seems to be the most important fac-
tor in determining the fate of disease aggressiveness of DLBCL. 
Though little is known about the key role of HOTAIR in the ma-
lignant lymphoma, HOTAIR might be involved in regulation 
of various genes in the lymphomagenesis. Further study should 
follow to determine the explicit mechanism among the sophisti-
cated modulatory networks of c-MYC, PRC2, H3K27me3, and 
HOTAIR.
Recent evidence has shown that inhibition of EZH2 methyl-
transferase activity provides a potential target therapy for EZH2-
deregulated lymphomas. In addition, the pharmacological inhi-
bition of EZH2 activity results in a decrease of global H3K27me3 
levels and a reactivation of silenced PRC2 gene targets, and it in-
hibits growth of DLBCL cells.16,17 From these overall findings as 
well as the present findings, HOTAIR may also be used in a tar-
get therapy by modulating the c-MYC–EZH2/PRC2 loop in a 
subset of DLBCLs with a high level of H3K27me3. 
In conclusion, we found frequent expression of PRC2 pro-
Table 2. Cox proportional hazard analyses of overall survival 
Variable Category
Univariate analysis
p-value
Multivariate analysis
 p-value
HR 95% CI
Age > 60 vs ≤ 60 < .001 - - -
ECOG PS ≥ 2 vs < 2 < .001 - - -
Ann-Arbor stage III–IV vs I–II .003 - - -
Extranodal sites ≥ 2 vs < 2 .001 - - -
Lactate dehydrogenase Elevated vs normal < .001 - - -
IPI risk group 3–5 vs 0–2 < .001 < .001 3.5 1.9–6.3
Hans classification Non-GCB vs GCB .16 - - -
EBV Positive vs negative .611 - - -
BCL2 Positive vs negative .076 - - -
c-MYC Positive vs negative .032 - - -
c-MYC/BCL2 Co-expression vs no co-expression .006 .528 1.2 0.6–2.4
EZH2 High vs non-high .883 - - -
SUZ12 High vs non-high .028 .183 1.5 0.8–2.7
EED High vs non-high .25 - - -
H3K27me3 High vs non-high .01 .023 2 1.1–3.6
HOTAIR High vs non-high .004 .086 0.5 0.2–1.1
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; EBV, Ep-
stein-Barr virus; EZH2, enhancer of zeste homolog 2; SUZ12, suppressor of zeste 12 homolog; EED, embryonic ectoderm development; HOTAIR, hox tran-
script antisense intergenic RNA.
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teins and H3K27me3 and positive correlation between these 
proteins and c-MYC in DLBCLs. High expression of H3K27me3 
was determined as an independent predictor of poor prognosis, 
however, HOTAIR was associated with favorable overall surviv-
al, which can be partly explained by negative correlation with 
c-MYC. LncRNA HOTAIR expression could be one of the pos-
sible mechanisms to be involved in aggressive behavior of DLB-
CL via induction of H3K27me3 and EZH2-related PRC2 acti-
vation. 
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